Technology

 

DryNeb’s ability to deliver high dose, pure active ingredient drug, achieving rapid delivery is unmatched by any known commercial or in-development dry powder inhaler and clearly differentiates the technology.

 

Nob Hill Therapeutics is a Delaware Corporation, founded to develop and market DryNeb, a first-in-kind dry powder nebulizer to address large pulmonary drug delivery market opportunities. The company has exclusively licensed the technology from the University of New Mexico.

DryNeb™ vs. Aerosol Mist Nebulizers

Compact, handheld, portable DryNeb will replace cumbersome aerosol mist nebulizers.

The pulmonary route of drug delivery has been gaining much importance in the present day, as it enables targeted drug delivery directly to the lungs for both local and systemic treatment. Pulmonary drug delivery, as a noninvasive drug administration method, is characterized by its high bioavailability and fast action. It is increasingly used in modern clinical practice for improved treatment of local as well as systemic diseases. Traditional nebulizers dispense drugs in liquid form; while offering superior efficacy and consistent delivery despite patient’s ability to inhale, they have limited drug stability, are cumbersome, and require relatively long times to administer (e.g., 10-30 min). Small, handheld metered-dose inhalers (MDIs) that deliver pre-measured drug doses in a puff or spray form are popular on the relevant market; however, they have major disadvantages such as unpredictable delivery to the lungs and releasing environmentally hazardous gases (e.g., CFC, HFA). Existing dry powder inhalers (DPIs) are small and easy to carry and overcome some limitation of liquid nebulizers and MDIs; however, their performance is dependent on patients’ inhalation effort, and their product quality and drug loading are reduced due to the presence of large mass fractions of lactose coarse carrier particles, which are traditionally used to facilitate powder flow, metering, dosing, and downstream processing. With the long development history of nebulizers and inhalers in pulmonary drug delivery, innovative solutions are called for constantly to overcome the challenges and limitations of the nebulizers and inhalers on the market. Large pharmaceutical companies and startups are tirelessly seeking improvements and innovations.

Aspergillosis is an invasive pulmonary fungal infection that can occur in severely immunocompromised patients, and is the most common cause of mortality due to invasive fungal infections.

DryNeb is poised to be the next generation inhaled dry powder delivery platform. Limitations of existing inhaled drug delivery methods have created the opportunity for DryNeb, with its new approach. Our patented DryNeb technology solves both conventional nebulizer’s and inhaler’s major drawbacks. It uses a novel, yet simple, mechanism-of-action, i.e., it employs a magnetically responsive element which results in mechanical collisions within the dispersion chamber. It disperses the powder independently from the patient’s inhalation force, ensuring reproducible delivery no matter the lung function of the patient, and it is designed to emit powder from the device only when a patient inhales, thus no coordination required.

Nob Hill Therapeutics is planning on demonstrating its capability by taking to market a carefully selected antifungal drug/device combination product to address antifungal infections such as aspergillosis and cryptococcosis, for immunocompromised patients. Currently, there are no such antifungal products (dry powder drug delivery directly to the lung) on the market for these difficult to treat infections.

DryNeb’s ability to deliver high dose, pure active ingredient drug, achieving rapid delivery is unmatched by any known commercial or in-development dry powder inhaler and clearly differentiates the technology.

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Comments are closed.